Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Mondelez International
MDLZConsumer StaplesGenerated Jul 5, 2026, 08:56 PM UTC
MDLZ (Mondelez International) analytical snapshot. Revenue grew +14.4% YoY to $36.02B. 5-year revenue CAGR +6.8%; 10y CAGR +0.6%. Net margin at 13.77% (expanding ▲). Market cap $78.19B at $60.91 per share. Trailing P/E 16.83, P/S 2.17, P/B 3.04. EV/Operating income ≈ 16.65 (EV $91.59B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -10 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Market cap
$78.19B
1.28B shares
Price
$60.91
NMS
P/E (ttm)
16.83
Revenue (FY)
$36.02B
YoY +14.4%
Net margin
13.77%
▲ 0.39pp
Free cash flow
$3.60B
10.00% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 5Stable
80% conf
Revenue grew +14.4% YoY to $36.02B. 5-year revenue CAGR +6.8%; 10y CAGR +0.6%. Net margin at 13.77% (expanding ▲).
- Revenue grew +14.4% YoY to $36.02B.
- 5-year revenue CAGR +6.8%; 10y CAGR +0.6%.
- Net margin at 13.77% (expanding ▲).
- Return on equity 18.41%, ROA 7.24%, ROIC 20.43%.
- Gross margin 38.22%, operating margin 15.28%.
- Free cash flow margin 10.00% ($3.60B).
- Net income up ▲ +82.5% YoY.
- Debt/equity 0.62, current ratio 0.54, net debt $13.40B.
- Asset turnover 0.51 — capital efficiency.
Revenue (FY)
$36.02B
YoY +14.4%
Net margin
13.77%
▲ 0.39pp
ROE
18.41%
ROA 7.24%
ROIC
20.43%
EPS (diluted)
$3.62
FY2025
Free cash flow
$3.60B
10.00% margin
Debt / equity
0.62
Cash $2.48B
Current ratio
0.54
Equity $25.75B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $34.24B | — | 36.79 | 9.47 | 6.38 | $1.92B | 7.80 |
| 2017 | $29.64B | -13.5% | 38.84 | 30.02 | 24.52 | $2.21B | 28.88 |
| 2018 | $25.92B | -12.5% | 38.98 | 9.85 | 6.31 | $1.61B | 6.29 |
| 2019 | $25.90B | -0.1% | 38.75 | 13.37 | 10.92 | $1.58B | 11.03 |
| 2020 | $25.94B | +0.2% | 39.91 | 12.77 | 12.79 | $2.85B | 12.18 |
| 2021 | $25.87B | -0.3% | 39.96 | 14.86 | 15.19 | $3.04B | 14.25 |
| 2022 | $26.58B | +2.8% | 39.30 | 14.50 | 13.37 | $3.10B | 12.58 |
| 2023 | $28.72B | +8.0% | 39.19 | 16.20 | 14.97 | $3.18B | 16.00 |
| 2024 | $31.50B | +9.7% | 35.92 | 11.22 | 8.63 | $3.00B | 9.59 |
| 2025 | $36.02B | +14.4% | 38.22 | 15.28 | 13.77 | $3.60B | 18.41 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $9.31B | +0.2% | — | 4.32% |
| Jun 30, 2025 | $18.30B | +3.8% | +96.5% | 5.70% |
| Jun 30, 2025 | $8.98B | -49.1% | -50.9% | 11.61% |
| Sep 30, 2025 | $28.04B | +4.5% | +212.1% | 6.37% |
| Sep 30, 2025 | $9.74B | -63.7% | -65.3% | 18.33% |
| Mar 31, 2026 | $10.08B | +8.2% | +3.4% | 5.56% |
Revenue (annual, SEC 10-K)
2016: 34,244
2017: 29,636
2018: 25,923
2019: 25,896
2020: 25,938
2021: 25,868
2022: 26,581
2023: 28,720
2024: 31,496
2025: 36,016
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 1,920
2017: 2,214
2018: 1,614
2019: 1,579
2020: 2,853
2021: 3,040
2022: 3,101
2023: 3,176
2024: 3,002
2025: 3,602
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 4, 2026. Latest quarterly report (10-Q) filed Apr 28, 2026. 22 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 4, 2026.
- Latest quarterly report (10-Q) filed Apr 28, 2026.
- 22 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Mondelez International; broad institutional reporting.
- Recent filers include WINNOW WEALTH LLC, UNITED BANK INC /WV/, SOUTHEASTERN ASSET MANAGEMENT INC/TN/.
- 3 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 17 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 4, 2026
Annual report
Latest 10-Q
Apr 28, 2026
8-K (recent)
22
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
3
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| WINNOW WEALTH LLC | 13F-HR | Aug 21, 2025 |
| UNITED BANK INC /WV/ | 13F-HR | Jan 23, 2013 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | May 15, 2014 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | Feb 13, 2015 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | Aug 14, 2014 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 18, 2026 | 8-K | 8-K |
| May 26, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Feb 18, 2026 | 8-K | 8-K |
| Feb 3, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Oct 28, 2025 | 8-K | 8-K |
| Jul 29, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -50Deteriorating
72% conf
3 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 26 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 5 filing(s).
- Gross margin expansion: Gross margin expanded +2.3%pp (from 35.9% to 38.2%), indicating improved pricing power, cost efficiency, or favorable product mix.
- Goodwill is 34% of total assets: Goodwill of $24.23B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 7 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$36.02B
+14.4% YoY
Gross profit
$13.76B
+21.7% YoY
Operating income
$5.50B
+55.7% YoY
Net income
$4.96B
+82.5% YoY
Operating cash flow
$4.71B
+20.6% YoY
Capex
$1.11B
+22.7% YoY
Total assets
$68.50B
-4.1% YoY
Total liabilities
$41.54B
-3.5% YoY
Filing quality score
75/100
7 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $31.50B | $36.02B | $4.52B | +14.4% |
| Gross profit | $11.31B | $13.76B | $2.45B | +21.7% |
| Operating income | $3.53B | $5.50B | $1.97B | +55.7% |
| Net income | $2.72B | $4.96B | $2.24B | +82.5% |
| Operating cash flow | $3.91B | $4.71B | $806.0M | +20.6% |
| Capex | $906.0M | $1.11B | $206.0M | +22.7% |
| Total assets | $71.39B | $68.50B | $-2.89B | -4.1% |
| Total liabilities | $43.02B | $41.54B | $-1.49B | -3.5% |
| Long-term debt | $15.25B | $15.88B | $625.0M | +4.1% |
| Cash & equivalents | $1.24B | $2.10B | $857.0M | +68.9% |
| Stockholders equity | $28.33B | $26.93B | $-1.40B | -4.9% |
| Inventory | $3.62B | $3.83B | $212.0M | +5.9% |
| Accounts receivable | $3.63B | $3.87B | $240.0M | +6.6% |
| R&D expense | $346.0M | $380.0M | $34.0M | +9.8% |
| SG&A expense | $7.38B | $8.00B | $618.0M | +8.4% |
| Interest expense | $428.0M | $550.0M | $122.0M | +28.5% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1, ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1, DebtInstrumentFaceAmount, GainLossOnFairValueHedgesRecognizedInEarnings, HedgedLiabilityFairValueHedge, HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease, StockIssuedDuringPeriodValueShareBasedCompensation |
| Removed | AdvertisingExpense, BusinessCombinationAcquisitionRelatedCosts, BusinessCombinationContingentConsiderationLiability, CommonStockCapitalSharesReservedForFutureIssuance, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit, DeferredForeignIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 3 | 0 | NEW |
| Material weakness in internal controls | high | 26 | 2 | Ongoing |
| Restatement of financial statements | high | 5 | 0 | NEW |
| Impairment charge | medium | 71 | 8 | Ongoing |
| Restructuring | medium | 112 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 62 | 0 | NEW |
| Related party transactions | low | 32 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 1
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $78.19B at $60.91 per share.
- ProPrice & TechnicalsPrice $60.91 — uptrend (above 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -10
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Mondelez International is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewLatest annual report (10-K) filed Feb 4, 2026..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow MDLZ stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Mondelez International MDLZ● you | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |